Loading...
01/11 03:35
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Biote's earnings call presents mixed signals. The company shows strong revenue growth and cost management, but guidance has been lowered, and net income has decreased. The software transition has affected procedure volumes, causing short-term disruptions. The lack of a shareholder return plan and uncertainties around new practitioner growth add to the neutral sentiment. However, the positive cash flow and gross margin improvements provide some optimism. With no market cap data, the overall prediction is neutral, considering the potential for recovery post-software transition and ongoing cost management efforts.
Revenue $49.8 million, up 9% from the prior year period. Growth driven by established top-tier clinics, despite headwinds from reduced procedure volume during the transition to upgraded clinical decision support software.
Procedure Revenue Growth Increased 5%, impacted by a reduction in procedure volume due to the transition to upgraded clinical decision support software and a focus on training existing practitioners.
Dietary Supplement Revenue Increased 10.2% year-over-year, benefiting from the transition of a portion of this business to the Amazon channel.
Gross Profit Margin 71.8%, a 247 basis point increase from the fourth quarter of 2023, reflecting cost savings from vertical integration of the 503B manufacturing facility and effective cost management.
Selling, General, and Administrative Costs (SG&A) $33.0 million, compared to $26.2 million in the fourth quarter of 2023, due to employee-related investments and additional legal expenses.
Net Income $3.5 million, down from $12.1 million in the fourth quarter of 2023, which included a $5.4 million gain due to the net change in the fair value of the earn out liability.
EPS (Earnings Per Share) $0.10 per diluted share, compared to $0.18 per diluted share in the fourth quarter of 2023.
Adjusted EBITDA Increased 11.4% to $15.1 million, with an adjusted EBITDA margin of 30.3%, up from 29.7% in the comparable quarter in 2023, primarily reflecting the operating leverage of the business model.
Cash Flow from Operations $45.2 million for fiscal year 2024, compared to $26.9 million for fiscal year 2023, indicating strong cash flow generation.
Cash and Cash Equivalents $39.3 million as of December 31, 2024, compared to $38.2 million as of September 30, 2024.
BioteRx wellness platform: Biote launched the proprietary BioteRx wellness platform, providing Biote-certified practitioners with a seamless platform for product ordering and inventory management, along with technical support, training, and educational resources.
Clinical decision support software: In September 2024, Biote introduced significant improvements to its proprietary clinical decision support software, featuring proprietary dosing algorithms that are unique in the marketplace.
Market expansion through Asteria Health acquisition: The acquisition of Asteria Health in 2024 marked an important inflection point, strengthening control over supply chain and product quality, and enabling vertical integration of internal manufacturing.
Internal manufacturing capacity: Biote has scaled up its internal manufacturing capacity to meet customer needs, with sufficient capacity to produce monthly pellet needs.
Cost efficiencies: Vertical integration of the 503B manufacturing facility has generated cost efficiencies and enhanced gross profit margin.
Focus on existing practitioners: Biote is focusing on training existing practitioners to enhance their capabilities and improve patient care, which has temporarily slowed new customer growth.
Revenue growth initiatives: Bret Christensen identified three key areas for 2025: maximizing value from top-tier providers, adding new practitioners, and driving revenue growth through improved accountability and consistency.
Competitive Pressures: Biote faces competitive pressures as it seeks to expand its market share in hormone optimization and therapeutic wellness. The company is focusing on enhancing its proprietary offerings and clinical decision support software to differentiate itself from competitors.
Regulatory Issues: The company operates in a highly regulated industry, which poses risks related to compliance and potential changes in regulations that could impact operations and product offerings.
Supply Chain Challenges: Biote's acquisition of Asteria Health aims to strengthen control over its supply chain and product quality, but any disruptions in the supply chain could affect production and delivery.
Economic Factors: The company anticipates that macroeconomic conditions may impact its business, particularly in terms of consumer spending on health and wellness products.
Transition Risks: The transition to upgraded clinical decision support software has led to a reduction in procedure volume, which may affect revenue growth in the short term as clinics adapt to the new system.
Investment Risks: Increased levels of investment in sales and marketing are expected to drive new customer growth, but this may lead to short-term financial strain before achieving desired results.
Acquisition of Asteria Health: Strengthened control over supply chain and product quality, began vertically integrating internal manufacturing, generating cost efficiencies and enhancing gross profit margin.
BioteRx wellness platform: Launched a proprietary platform for product ordering and inventory management, providing technical support, training, and educational resources to practitioners.
Clinical decision support software improvements: Introduced significant updates to software, featuring proprietary dosing algorithms to enhance patient care and expand treatment alternatives.
Focus on practitioner training: Intensifying efforts to add new practitioners and enhance training programs to broaden the network and reinvigorate procedure revenue growth.
Revenue growth initiatives: Strengthening accountability and improving consistency within the commercial organization to drive revenue growth.
2025 Revenue Outlook: Expected revenue of $202 million to $208 million.
2025 Adjusted EBITDA Outlook: Expected adjusted EBITDA of $59 million to $64 million.
Procedure Revenue Growth: Expected increase of approximately 2% to 4% from 2024.
Dietary Supplement Revenue Growth: Expected increase of approximately 5% to 10% from 2024.
First Quarter 2025 Revenue: Expected to be slightly higher compared to the first quarter of 2024.
First Quarter 2025 Adjusted EBITDA: Expected to be approximately 5% lower compared to the first quarter of 2024.
Shareholder Return Plan: Biote Corp. did not announce any specific share buyback program or dividend program during the earnings call.
The earnings call reveals several concerns: declining net income and adjusted EBITDA, high attrition rates, and procedural revenue decline. Although there's positive cash flow and growth in the supplements business, the lack of clear guidance on procedural growth and high attrition are worrying. The Q&A highlighted ongoing challenges with sales turnover and attrition, which could continue to pressure the stock. Overall, despite some positives, the negatives outweigh them, leading to a negative sentiment.
The earnings call presents mixed signals. Financial metrics show improvement, with increased gross profit margin and reduced SG&A expenses, but cash reserves have decreased. The Q&A reveals concerns about clinic attrition and lack of clear improvement timelines. Despite positive restructuring efforts, tangible results are yet to manifest. The stock price impact is likely neutral as the market waits for clearer signs of recovery.
The earnings call presents a mixed picture: strong dietary supplement revenue growth and improved gross profit margins are offset by declining procedure revenue and increased SG&A expenses. The strategic restructuring and vertical integration are positive, but operational risks and potential challenges in achieving procedure revenue growth temper optimism. The Q&A reveals management's cautious stance on procedure revenue growth and a lack of clarity on certain inefficiencies. Given these factors, the stock price is likely to remain stable, resulting in a neutral sentiment.
Biote's earnings call presents mixed signals. The company shows strong revenue growth and cost management, but guidance has been lowered, and net income has decreased. The software transition has affected procedure volumes, causing short-term disruptions. The lack of a shareholder return plan and uncertainties around new practitioner growth add to the neutral sentiment. However, the positive cash flow and gross margin improvements provide some optimism. With no market cap data, the overall prediction is neutral, considering the potential for recovery post-software transition and ongoing cost management efforts.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
